Breast Cancer
Dr. Wassim Mchayleh on ASCENT-03: Evaluating Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer
From Podium To Practice - Breast Cancer ESMO Part 1 In this overview, Dr. Wassim Mchayleh breaks down the ASCENT-03 trial, highlighting the rationale for...
Dr. Wassim Mchayleh on TROPION-Breast02: Evaluating Dato-DxD in Metastatic Breast Cancer
From Podium To Practice - Breast Cancer ESMO Part 2 In this segment, Dr. Wassim Mchayleh reviews the design and objectives of TROPION-Breast02, highlighting how...
Dr. Wassim Mchayleh on VIKTORIA-1: Gedatolisib Combinations in HR+/HER2- Metastatic Breast Cancer
From Podium To Practice - Breast Cancer ESMO Part 3 In this overview, Dr. Wassim Mchayleh explains the design and significance of VIKTORIA-1, a key...
Dr. Wassim Mchayleh on evERA: Exploring Elacestrant Combinations in ER+/HER2– Metastatic Breast Cancer
From Podium To Practice - Breast Cancer ESMO Part 4 In this overview, Dr. Wassim Mchayleh breaks down the evERA trial, which evaluates elacestrant-based combination...
Dr. Sara Tolaney & Dr. Wassim Mchayleh on Trial Design & Patient Populations in ASCENT-03 and TROPION-Breast02
From Podium To Practice - Breast Cancer ESMO Part 5 In this discussion, Dr. Wassim Mchayleh of AdventHealth introduces Dr. Sara Tolaney of Dana-Farber Cancer...
Interpreting Efficacy & Ethical Design: Drs. Tolaney and Mchayleh on ORR, PFS, OS & Crossover Strategy
From Podium To Practice - Breast Cancer ESMO Part 6 In this discussion, Dr. Wassim Mchayleh and Dr. Sara Tolaney dissect the efficacy signals from...
Differentiated Thyroid Cancer
Q&A with Dr. Greg Randolph: How Neural Monitoring Is Changing Thyroid Cancer Surgery
In this Q&A, Dr. Greg Randolph discusses the growing role of neural monitoring in managing advanced thyroid cancer. He describes how nerve mapping before visualization,...
Real-World Risks & Future Tech in Thyroid Cancer Surgery with Dr. Greg Randolph
In this video, Dr. Greg Randolph of Harvard Medical School discusses real-world considerations for neoadjuvant therapy in advanced thyroid cancer, emphasizing the differences between controlled...
Neoadjuvant Therapy in Advanced Thyroid Cancer: Surgical Impact & Evolving Challenges
In this video, Dr. Greg Randolph of Harvard Medical School explains how modern neoadjuvant therapies—including lenvatinib and targeted agents for RET-altered and anaplastic thyroid cancers—are...
Pancreatic Cancer
Targeting KRAS in Pancreatic Cancer
KRAS has long defined pancreatic ductal adenocarcinoma—and for decades, it was considered untouchable. Dr. Nicholas Hornstein discusses how new KRAS-targeted strategies emerging around ESMO 2025...
Colorectal Cancer
Dr. Nicholas Hornstein: A Turning Point in Colorectal Cancer Treatment
Dr. Nicholas Hornstein highlights how ESMO 2025 delivered several practice-changing moments in colorectal cancer, including the first meaningful step toward immunotherapy efficacy in microsatellite-stable disease...